Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6488results about "Antiinfectives" patented technology

Lipid nanoparticles comprising coding RNA molecules for use in gene editing and as vaccines and therapeutic agents

PCT designated stage expiredWO2024263729A1Organic chemistryAntiinfectivesDiseaseNanoparticle
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.
Owner:RENAGADE THERAPEUTICS MANAGEMENT INC

Dry powder composition comprising long-chain RNA

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry 10 powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
Owner:CUREVAC SE

Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein

The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT / L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Owner:BOEHRINGER INGELHEIM INT GMBH

Stem cell nano-vesicle capable of being precisely controlled in quality and application of stem cell nano-vesicle

PendingCN119530147AUniform sizeTypical cell membrane-like vesicle structureOrganic active ingredientsCosmetic preparationsPhospholipinTissue repair
The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.
Owner:NANJING SAILIKANG BIOMEDICAL TECHNOLOGY CO LTD

Phyllanthus emblica fermentation liquor and preparation method thereof

The invention relates to the technical field of deep processing of phyllanthus emblica, in particular to phyllanthus emblica fermentation liquor and a preparation method thereof. The preparation method comprises the following steps: uniformly mixing crushed phyllanthus emblica pulp with water; after sterilization, adding lactic acid bacteria mixed powder for fermentation treatment; cellulase is added into the fermentation liquor for hydrolysis, and hydrolysate is obtained after enzyme deactivation; the hydrolysate is subjected to extraction treatment and solid-liquid separation, and the phyllanthus emblica fermentation liquor is obtained. By adopting the method disclosed by the invention, 107.11 mg of gallic acid, 360.76 mg of polyphenol and 65.56 mg of flavone can be extracted from each gram of the phyllanthus emblica raw material respectively, and the contents of gallic acid, polyphenol and flavone are increased by about 2.1 times, 4.5 times and 1.7 times respectively compared with those of gallic acid, polyphenol and flavone which are not subjected to fermentation treatment; the phyllanthus emblica fermentation liquor has alpha-glucosidase inhibitory activity, xanthine oxidase inhibitory activity, pancreatic lipase inhibitory activity, tyrosinase inhibitory activity and antioxidant activity; the phyllanthus emblica fermentation liquor is good in taste and flavor, and has the functions of reducing blood sugar, blood fat and uric acid and resisting oxidation.
Owner:XIAMEN YUANZHIDAO BIOTECHNOLOGY CO LTD

Composite hydrogel as well as preparation method and application thereof

The invention discloses composite hydrogel as well as a preparation method and application thereof. The curcumin-EGCG composite hydrogel is prepared by forming a complex through hydrogen-bond interaction between gelatin and epigallocatechin gallate and carrying out chemical crosslinking through Schiff base reaction of curcumin and gelatin. The composite hydrogel disclosed by the invention has a self-healing characteristic or viscosity and a shear thinning characteristic, and is beneficial to local application. The composite hydrogel is loose and porous in structure, the drug loading rate can be increased, the drug can be slowly and controllably released, the treatment effect of the composite hydrogel in androgenetic alopecia is promoted, meanwhile, the solubility of a drug monomer can be remarkably improved, and the problem that the drug solubility is low is solved. The composite hydrogel provided by the invention provides an effective transdermal drug delivery preparation for treatment of skin diseases, and has good clinical application prospects and development values.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Topical ocular delivery methods and devices for use in the same

ActiveUS12186234B2Senses disorderAntiinfectivesOphthalmic AgentsOphthalmology
Methods of administering a liquid formulation of an ophthalmic agent to a topical ocular location of an eye are provided. Aspects of the methods include delivering to the topical ocular location a dose of the liquid formulation that can be wholly accommodated by the tear film of the eye. Devices and kits for practicing the methods are also provided. The methods, compositions and kits find use in a variety of applications, including therapeutic, diagnostic and cosmetic applications.
Owner:BAUSCH & LOMB IRELAND LIMITED

Whitmania pigra destabilizing enzyme fusion protein and application thereof

The invention discloses a destabilizing enzyme fusion protein with improved activity, and the amino acid sequence of the destabilizing enzyme fusion protein is as shown in SEQ ID No.3 or SEQ ID No.5. According to the destabilizing enzyme fusion protein disclosed by the invention, the bacteriostatic activity, thrombolytic activity and isopeptidase activity of the destabilizing enzyme fusion protein are improved by optimizing the expression strategy and modifying the sequence of destabilizing enzyme Wpdestalase from whitmania pigra; and the application prospect and the application space of the Wpestabase are improved.
Owner:GUIZHOU EDUCATION UNIV

Protein tyrosine phosphatase inhibitor, pharmaceutical composition and application thereof

PendingCN119176787AOrganic active ingredientsNervous disorderDiseaseEnzyme Inhibitor Drugs
The invention belongs to the field of medical chemistry, and particularly discloses a protein tyrosine phosphatase inhibitor, a pharmaceutical composition and application of the protein tyrosine phosphatase inhibitor, and the protein tyrosine phosphatase inhibitor is a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound. The invention also discloses a method for using the protein tyrosine phosphatase inhibitor to treat cancers, metabolic diseases and other related diseases. # imgabs0 #
Owner:ALICORN PHARMACEUTICAL CO LTD

Methods of treating a ras protein-related disease or disorder

The disclosure features methods of treating RAS disorders using Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders (e.g., cancer) including combinations of Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound A is a compound having the following structure:
Owner:REVOLUTION MEDICINES INC

Machine learning for real-time decision support

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor(s) determining that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in an electronic health record (EHR) system communicatively coupled to the one or more processors. The processor obtains descriptive information relating to a patient. The processor selects a pharmacokinetic model. The processor applies the pharmacokinetic model and utilizes the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection. The processor generates rankings for the drug therapies and determines if the current drug regimen comprises a probability above a threshold. The processor generates a new order.
Owner:PRXCISION INC

Novel recruitment element of ubiquitin ligase and application of novel recruitment element

The invention discloses a novel recruitment element of ubiquitin ligase and application of the recruitment element, such as application in preparation of targeted protein degradation drugs, including PROTAC drugs. The inventor creatively discovers that the compound recruits ubiquitin ligase MDM2 through interaction with NCL, and further experiments discover that the compound can be used as a novel recruitment element of MDM2 and can be used in the aspects of preparation of targeted protein degradation agents and the like. The inventor prepares the targeted protein degradation agent by utilizing the discovery, and the experiment finds that the prepared targeted protein degradation agent can effectively mediate the degradation of the target protein through a ubiquitin-proteasome way, realizes the treatment of target protein related diseases (such as tumors), and has a very good application prospect in the field of medicines.
Owner:SHENZHEN LINGGENE BIOTECH CO LTD

Compositions and methods for modulating cytokines

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.
Owner:FLAGSHIP ENTREPRENEURSHIP & INNOVATION NO 7 CO LTD

Whitmania pigra destabilizing enzyme fusion protein and application thereof

The invention discloses a destabilizing enzyme fusion protein with improved activity, and the amino acid sequence of the destabilizing enzyme fusion protein is as shown in SEQ ID No.3 or SEQ ID No.5. According to the destabilizing enzyme fusion protein disclosed by the invention, the bacteriostatic activity, thrombolytic activity and isopeptidase activity of the destabilizing enzyme fusion protein are improved by optimizing the expression strategy and modifying the sequence of destabilizing enzyme Wpdestalase from whitmania pigra; and the application prospect and the application space of the Wpestabase are improved.
Owner:GUIZHOU EDUCATION UNIV

STING agonist prodrug compound, liposome preparation and preparation method thereof

The invention relates to a STING agonist prodrug compound, a liposome preparation and a preparation method thereof. Specifically, the invention relates to an STING agonist prodrug compound shown in a general formula (I) or a pharmaceutically acceptable salt thereof, a liposome preparation thereof and application of the STING agonist prodrug compound or the pharmaceutically acceptable salt and the liposome preparation in preparation of drugs for treating STING-related diseases. The prodrug compound disclosed by the invention can be rapidly hydrolyzed under the induction of esterase to release an active ingredient MSA-2, and has a good STING protein excitation function. # imgabs0 #
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

Anti-CD3 antibody and use thereof

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.
Owner:HEFEI TG IMMUNOPHARMA CO LTD

Compounds that participate in cooperative binding and uses thereof

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiments, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein (e.g., do not show detectable binding in mammalian cells absent the compound). In some embodiments, provided compounds “re-program” presenter protein binding to greatly enhance interaction with a particular target with which it may have some interaction absent the compound. Interactions achieved through such reprogramming result in an ability to modulate the activity of these new targets.
Owner:REVOLUTION MEDICINES INC

Nitrogen-containing fused ring compound, preparation method and application

The invention discloses a nitrogen-containing fused ring compound as well as a preparation method and application thereof, and particularly relates to a nitrogen-containing fused ring compound as shown in a general formula I, or pharmaceutically acceptable salt thereof, or enantiomers, diastereoisomers, tautomers, torsion isomers, solvates, polymorphic substances or prodrugs thereof, and a preparation method and application thereof in pharmacy, and particularly relates to a nitrogen-containing fused ring compound as shown in a general formula I, or pharmaceutically acceptable salts thereof, or enantiomers, diastereoisomers, tautomers, torsion isomers, solvates, polymorphic substances or prodrugs thereof. Wherein the definition of each group is described in the specification. # imgabs0 #
Owner:RUDONG RINGENE PHARMA CO LTD

Polypeptide variants and uses thereof

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and / or agonistic activity.
Owner:GENMAB BV

Nucleic acid nano-microsphere as well as preparation method and application thereof

The invention discloses nucleic acid nano microspheres as well as a preparation method and application thereof, and belongs to the technical field of nano delivery. The preparation method comprises the following steps: carrying out first mixing on nucleic acid and part of water, and carrying out pretreatment and curing to form nucleic acid semi-solid gel; melting the nucleic acid semi-solid gel at 45-80 DEG C, and adjusting the pH value to 4-6 to form a phase A; carrying out second mixing on the spermidine-containing plant extract and the remaining water, and adjusting the pH value to 4-6 to form a phase B; and carrying out third mixing on the phase A, the phase B and an auxiliary agent to form the nucleic acid nano-microsphere, the nucleic acid nano-microsphere is prepared from the following components in percentage by mass: 0.5 to 8 percent of nucleic acid, 0.1 to 7.5 percent of a plant extract containing spermidine, 0 to 6 percent of an auxiliary agent and 78.5 to 99.4 percent of water, the mass ratio of the nucleic acid to the plant extract containing spermidine is (1-10): 1. The nucleic acid nano-microsphere has improved transdermal effect and stability, and can be used for transdermal drug delivery.
Owner:BEIJING WEIYE INNOVATION TECH CO LTD